A Multi-Center, Double-Masked, Randomized, Phase 2 Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo for the Treatment of Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 31 Mar 2017
At a glance
- Drugs ST 266 (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Noveome
- 13 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 05 Dec 2016 Planned End Date changed from 1 Feb 2017 to 1 Mar 2017.
- 02 Dec 2016 New trial record